The distribution of stilbamidine in the livers of normal and sarcoma-bearing mice.


In experiments preliminary to the possible use of carbon-14-labeled Stilbamidine in the treatment of humans with multiple myeloma (2, 9, 26) it was found in normal mice that no abnormal concentra tion of Stilbamidine persisted in any tissue and that over 90 per cent of the injected radioactivity was excreted within a month (20). A tracer dose of C14-labeled… (More)


5 Figures and Tables